Valneva presented its chikungunya vaccine candidate, VLA1553, on November 18 and 19, 2021 during the American Society of Tropical Medicine & Hygiene (ASTMH) 2021 Annual Meeting.
Valneva’s Chief Medical Officer, Juan Carlos Jaramillo, presented: “Chikungunya: Phase III Clinical Development of a Single-shot Live-attenuated Vaccine” and Martina Schneider, Clinical Strategy Manager at Valneva, presented: “Chikungunya: Safety up to Day 29 of Phase III Clinical Development of a Single-shot Live-attenuated Vaccine.
The vaccine candidate induced protective CHIKV neutralising antibody titres in 98.5% of trial participants
At the beginning of August 2021, Valneva announced positive topline results for the Phase III trial of VLA1553. The vaccine candidate induced protective CHIKV neutralising antibody titres in 98.5% of trial participants after a single vaccination and was well tolerated across all age groups.
Image credit: Boris Smokrovic
